Interaction between trouble sleeping and diabetes on metabolic dysfunction-associated fatty liver disease and liver fibrosis in adults results from the National Health and Nutrition Examination Survey 2017–2018

Cui Zhang,Lili Cao,Bo Xu,Wei Zhang
DOI: https://doi.org/10.1097/meg.0000000000002860
2024-10-31
European Journal of Gastroenterology & Hepatology
Abstract:Nonalcoholic fatty liver disease (NAFLD) is a significant global health issue affecting individuals of all ages [ 1 ]. It is characterized by the accumulation of fat in the liver among those who do not drink alcohol, with potential consequences ranging from simple steatosis to more severe conditions such as nonalcoholic steatohepatitis (NASH), which can progress to advanced stages such as fibrosis, cirrhosis, and liver cancer [ 2 ]. Research indicates that approximately 25% of the global population may have NAFLD [ 3 ], with approximately 59% of biopsied NAFLD patients showing signs of NASH [ 4 ]. Fibrosis, characterized by the excessive deposition of proteins in the liver tissue, is a crucial stage in the advancement of NAFLD and is closely linked to poor health outcomes, including an increased risk of hepatocellular carcinoma [ 5 ]. Recent advancements in hepatology have brought about a significant shift in the understanding of NAFLD. The term 'metabolic dysfunction-associated fatty liver disease (MAFLD)' has been introduced as a more inclusive label for this condition [ 6 ]. MAFLD encompasses a range of fatty liver diseases linked to metabolic irregularities, extending beyond the mere absence of alcohol intake [ 7 ]. This shift in terminology underscores the crucial role of metabolic factors such as obesity, type 2 diabetes, and insulin resistance in the onset and advancement of fatty liver disease [ 8 ]. As NAFLD is becoming the leading cause of chronic liver disease in Western nations, affecting over 30% of the world's adult population [ 9 ], the urgency to address this public health concern is evident. Efforts to prevent the progression of fibrosis have become central to reducing liver-related mortality. By understanding and addressing the underlying factors contributing to MAFLD development, interventions can be targeted to prevent the progression of the disease to more severe stages, ultimately improving outcomes in individuals with MAFLD.
gastroenterology & hepatology
What problem does this paper attempt to address?